SCHEMBL249033

SCHEMBL249033

NC(=NO)NC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3915786 0.75 SIGMAR1 (0.96)
SCHEMBL3319896 0.74 SIGMAR1 (1.00)
SCHEMBL3319901 0.74 SIGMAR1 (1.00)
SCHEMBL26456614 0.74 SIGMAR1 (1.00)
SCHEMBL13497354 0.70 SIGMAR1 (0.41)
SCHEMBL20111343 0.67
SCHEMBL9060289 0.67 SIGMAR1 (0.58)
SCHEMBL19861948 0.67
SCHEMBL11301865 0.65 SIGMAR1 (0.61)
SCHEMBL11297848 0.65 SIGMAR1 (0.61)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010035047-A1 BINARY COMPOSITIONS COMPRISING AN NO-DONOR AND AN A-SMASE INHIBITOR FOR THE TREATMENT OF RESPIRATORY DISEASES PHARMAPATENTS GLOBAL LTD. (GB) 2010-04-01 WO claimed
WO-2008157537-A2 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC (US) 2008-12-24 WO claimed
WO-2008124505-A2 SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS,INC. (US) 2008-10-16 WO claimed
US-20260116886-A1 DEUTERATED sGC STIMULATORS TISENTO THERAPEUTICS INC (US) 2026-04-30 US disclosed
US-20260000653-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS TISENTO THERAPEUTICS INC (US) 2026-01-01 US disclosed
US-20250326761-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC (US) 2025-10-23 US disclosed
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 US disclosed
EP-4605394-A1 PYRIMIDINE SGC STIMULATORS Tisento Therapeutics Inc. (US) 2025-08-27 EP disclosed
EP-4605080-A1 TREATMENT OF MITOCHONDRIAL DISEASES WITH SGC STIMULATORS Tisento Therapeutics Inc. (US) 2025-08-27 EP disclosed
US-20250243205-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC (US) 2025-07-31 US disclosed
US-20250243228-A1 PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2025-07-31 US disclosed
US-20100215779-A1 Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention IRONWOOD PHARMACEUTICALS, INC. 2010-08-26 US disclosed
US-20100144864-A1 SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2010-06-10 US disclosed
US-20100081159-A1 Profiling reactive oxygen, nitrogen and halogen species ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC. 2010-04-01 US disclosed
WO-2010035047-A1 BINARY COMPOSITIONS COMPRISING AN NO-DONOR AND AN A-SMASE INHIBITOR FOR THE TREATMENT OF RESPIRATORY DISEASES PHARMAPATENTS GLOBAL LTD. (GB) 2010-04-01 WO disclosed
EP-2152266-A1 COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION Ironwood Pharmaceuticals, Inc. (US) 2010-02-17 EP disclosed
US-20090054450-A1 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2009-02-26 US disclosed
WO-2008157537-A2 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC (US) 2008-12-24 WO disclosed
WO-2008137318-A1 COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION IRONWOOD PHARMACEUTICALS, INC. (US) 2008-11-13 WO disclosed
WO-2008124505-A2 SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS,INC. (US) 2008-10-16 WO disclosed